Brief: BLS Pharmaceuticals Posts FY26 Adjusted EBITDA Of A$19 MLN
27/07/2026 02:45
BRIEF-BLS Pharmaceuticals Posts FY26 Adjusted EBITDA Of A$19 MLN July 27 (Reuters) - BLS Pharmaceuticals Ltd BLS.AX:
REPORTS QTRLY REVENUE OF A$22.5 MILLION
REPORTS FY26 ADJUSTED EBITDA OF A$19 MILLION AT TOP END OF GUIDANCE
Further company coverage: BLS.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BLS Pharmaceuticals
See all newsBrief: BLS Pharmaceuticals Posts Q1 FY27 Revenue A$26.7M
Brief: BLS Pharmaceuticals Reports Record Q1 FY27 Revenue Of A$26.7 Million
Australia's BLS Pharmaceuticals extends gains on upbeat outlook, strong results
Brief: BLS Pharmaceuticals Sees FY27 Adjusted. EBITDA Margin 23% - 26%
Brief: BLS Pharmaceuticals Posts FY Net Profit After Tax Of A$15.4 MLN